Johnson & Johnson (JNJ) Is Amazing, Says Jim Cramer

We recently published 10 Stocks on Jim Cramer’s Radar.  Johnson & Johnson (NYSE:JNJ) is one of the stocks that on Jim Cramer’s radar.

Pharma giant Johnson & Johnson (NYSE:JNJ)’s shares are up by 53% over the past year and by 15% year-to-date. Over the past couple of months, Cramer has turned optimistic about the company. Some factors that have driven his opinion include Johnson & Johnson (NYSE:JNJ)’s cancer drug portfolio and its orthopedic spinoff. Recently, RBC Capital raised Johnson & Johnson (NYSE:JNJ)’s share price target to $255 from $240 and kept an Outperform rating on the shares. The bank pointed out that the pharmaceutical company had strong finances to navigate its legal woes. Like RBC, Bank of America also raised Johnson & Johnson (NYSE:JNJ)’s share price target. It bumped the target to $227 from $221 and kept a Neutral rating on the stock. According to BofA, the firm’s organic growth was leading to healthier multiples. Johnson & Johnson (NYSE:JNJ)’s full-year revenue in 2025 grew by 6% to $94.2 billion, while the firm outlined that revenue could sit at $100.5 billion in 2026. Cramer continues to be enamored by the pharma company as he briefly remarked:

Trong Nguyen / Shutterstock.com

“JNJ is amazing.”

While we acknowledge the potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.